<DOC>
	<DOCNO>NCT00984412</DOCNO>
	<brief_summary>Refractory acute leukemia ( AL ) occur significant percentage AL patient present therapeutic challenge . Allogeneic stem cell transplantation ( allo-SCT ) curative option patient . Although many patient refractory AL undergo myeloablative SCT initially achieve complete remission , relapse later , long-term disease free survival poor . In order achieve good leukemic control , transplant center employ post transplant early withdrawal anti-GVHD immunosuppression ; hence expose patient high risk GVHD associate morbidity mortality . This study try address common scenario , namely early late relapse . The investigator try attain well leukemic control re-inducing patient , 6 week 1st transplant myeloablative treatment ( busulfex thiotepa ) follow allogeneic stem cell support ( transplant II ) .</brief_summary>
	<brief_title>Allo-Allo Tandem Bone Marrow Transplant ( BMT )</brief_title>
	<detailed_description>The effect feasibility oExperimental design method f allo-allo tandem match stem cell transplantation ( AATT ) patient refractory leukemia evaluate clinical setting . The current study limit patient refractory disease receive fail 2 line salvage therapy , good performance status young 50 year old . Only patient achieve complete remission transplant I , major organ dysfunction acceptable performance status , treat transplant II . Close monitor strict stopping rule include case excess transplant relate morality , acute chronic GVHD graft failure employ . Treatment schedule : 15 patient ( divide 2 cohort , see ) match family member unrelated donor include single arm open phase I/II trial . Conditioning protocol : All patient prepare sequential conditioning protocol : Transplant I : Cy-TBI follow Transplant II : Busulfan-thiotepa .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>1 . Patient age 350 year old refractory acute leukemia ( primary refractory refractory relapse I II ) unresponsive 2 salvage line match donor ( relate unrelated , match define 8/8 HLA matching ) . 2 . A donor willing capable donate peripheral blood stem cell preferably also bone marrow cell , lymphocyte indicate . 3 . Each patient / patient 's guardian must sign write informed consent . 4 . Patients must ECOG PS â‰¤ 1 ; Creatinine &lt; 1.5 mg/dl ; Ejection fraction &gt; 45 % ; DLCO &gt; 70 % predict ; Serum bilirubin &lt; 2 mg/dl ; elevate GPT GOT &lt; 2 x normal value transplant I . 1 . Not fulfil inclusion criterion . 2 . In complete good partial remission . 3 . Beyond 2nd relapse . 4 . Received &gt; 2 line salvage therapy . 5 . Active CNS involvement leukemia 6 . Active lifethreatening infection . 7 . Overt untreated infection . 8 . HIV seropositivity , Hepatitis B C antigen positivity evidence active hepatitis . 9 . Donor contraindication ( HIV seropositive confirm Western Blot , Hepatitis B antigenemia , HCV , evidence bone marrow disease , unable donate bone marrow peripheral blood due concurrent medical condition ) . 10 . Previous autologous allogeneic stem cell transplantation . 11 . Inability comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>